Quantbot Technologies LP Buys 193 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quantbot Technologies LP boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,754.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 204 shares of the biopharmaceutical company’s stock after purchasing an additional 193 shares during the quarter. Quantbot Technologies LP’s holdings in Alnylam Pharmaceuticals were worth $56,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $26,000. Huntington National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $42,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $45,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,370 shares of company stock valued at $2,100,703. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ALNY shares. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Scotiabank boosted their price target on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $256.26 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The stock has a market cap of $33.05 billion, a PE ratio of -97.81 and a beta of 0.32. The firm has a 50-day moving average of $269.12 and a 200-day moving average of $245.29. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the previous year, the business earned $1.15 EPS. The firm’s revenue was down 33.3% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.